Roche affirms sales outlook amid doubts about its future

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 22 Oct, 15:20 UTC

Lower-than-expected sales of Xolair stood out as the Swiss drugmaker readies for an onslaught of generic competition for top products.